Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

57 results about "Spliceosome complex" patented technology

A spliceosome is a large and complex molecular machine found primarily within the splicing speckles of the cell nucleus of eukaryotic cells. The spliceosome is assembled from snRNAs and SR protein. The spliceosome removes introns from a transcribed pre-mRNA, a type of primary transcript.

Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing

InactiveUS20060234247A1Reduce lungReduce liver pathologySugar derivativesMicrobiological testing/measurementDiseaseRNA Trans-Splicing
The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention include those genetically engineered to interact with SERPINA1 target pre-mRNA so as to result in correction of SERPINA1 genetic defects responsible for AAT deficiency. The PTMs of the invention may also comprise sequences that are processed out of the PTM to yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs. Such duplexed siRNAs are designed to reduce the accumulation of toxic AAT protein in liver cells. The methods and compositions of the present invention can be used in gene therapy for correction of SERPINA1 disorders such as AAT deficiency.
Owner:VIRXSYS

Method for detecting variable spliceosome in third generation full-length transcriptome

ActiveCN105389481AEfficient access to shear structuresPerfect commentSequence analysisSpecial data processing applicationsReference genome sequenceGene model
The invention discloses a method for detecting a variable spliceosome in a third generation full-length transcriptome. The method comprises the following steps: merging original annular test sequences with joints removed to form a monomolecular transcript sequence, and screening a third generation full-length transcript sequence; comparing the third generation full-length transcript sequence with a reference genome sequence, and screening a third generation full-length transcript sequence having coverage and similarity with the reference genome sequence larger than preset thresholds; carrying out splicing false positive filtration and DNA contamination filtration on the screened third generation full-length transcript sequence; and carrying out gene annotation and variable spliceosome annotation on the filtered third generation full-length transcript sequence. An overlong read length of a third generation sequencing technology mentioned in the method disclosed by the invention is large enough to cover most RNA, the third generation full-length transcript sequence can be obtained by SMRT sequencing transcriptomes without being assembled, and a splicing structure of a gene can be effectively obtained by third generation transcriptome sequencing, and more perfect gene model annotation can be constructed.
Owner:嘉兴菲沙基因信息有限公司

Methods and compositions for use in spliceosome mediated RNA trans-splicing

The present invention provides methods and compositions for delivery of synthetic pre-trans-splicing molecules (synthetic PTMs) into a target cell. The compositions of the invention include synthetic pre-trans-splicing molecules (PTMs) with enhanced stability against chemical and enzymatic degradation. The synthetic PTMs are designed to interact with a natural target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA).
Owner:VIRXSYS

Method for rapidly analyzing eukaryotic protein genomic data

The invention provides a method for rapidly analyzing eukaryotic protein genomic data, and belongs to the technical field of protein genomic data analysis methods. According to the method for rapidlyanalyzing eukaryotic protein genomic data, II-type credible peptide fragments are obtained by adoption of a prokaryote multi-group data arrangement method and a screening method; and three different genome replying methods for the aims of predicting new genes, variant spliceosomes and point mutation genes and correcting structures of annotated genes are designed. The method provided by the invention is suitable for any sequenced eukaryon, and through a variant spliceosome and point mutation gene prediction method, the coverage degree of authentication is improved; by adoption of different relatively strict false positive control strategies, the credibility of the authentication is improved; and through predicting and correcting original mass spectrometric data, final new genes, variant spliceosome and point mutation genes, annotated gene structure series are analyzed, so that rapid authentication and analysis of eukaryotic mass spectrometric data are really realized.
Owner:INST OF AQUATIC LIFE ACAD SINICA

Application of FBXO31 gene and related products in preparing gastric cancer diagnostic reagent

The invention relates to application of an FBXO31 gene and related products in preparing a gastric cancer diagnostic reagent. The related products of the FBXO31 gene are one or more of spliceosome of the FBXO31 gene, antisense oligodeoxynucleotide of the FBXO31 gene, mRNA (Messenger Ribonucleic Acid) of the FBXO31 gene, a protein of the FBXO31 gene, a peptide fragment encoded by the FBXO31 gene, an antibody of the protein of the FBXO31 gene, a regulating small molecular RNA related to the FBXO31 gene or an inhibitor of the regulating small molecular RNA related to the FBXO31 gene. The invention provides a novel concept of diagnosing gastric cancer and provides a novel path for researching and developing the gastric cancer diagnostic reagent.
Owner:SHANDONG UNIV

Reagent for diagnosing chronic myeloid leukemia blast crisis based on hnRNPA1 splicing variant and kit

The invention discloses application of No.8 exon skip / retained spliceosome (hnRNPA1-a and hnRNPA1-b) of hnRNPA1 in preparing a reagent for diagnosing chronic myeloid leukemia blast crisis or in a kitcontaining the diagnostic reagent. The reagent has higher sensitivity and specificity, can observe the chronic myeloid leukemia blast crisis more simply, accurately and early so as to timely take treatment means, and has higher clinical application value.
Owner:THE SECOND AFFILIATED HOSPITAL TO NANCHANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products